An insight into how the financial market sees ... - CLL Support

CLL Support

22,985 members39,471 posts

An insight into how the financial market sees the development of new CLL drugs

AussieNeil profile image
AussieNeilPartnerAdministrator
2 Replies

AbbVie developed a novel BCL-2 inhibitor drug named ABT-263 for treating CLL, then used the knowledge gained from phase I trials to develop the improved drug ABT-199. Trials were suspended this month when two patients unfortunately died from Tumor Lysis Syndrome:

bloomberg.com/news/2013-02-...

It's interesting to read that this company has one drug delivering over half of the company's income and they need another to reduce business risk.

fool.com/investing/general/...

How desperate a company might be for a new income stream isn't something that is likely to be high in the thoughts of those entering trials. Thankfully we do have in place appropriate processes to minimise the risk to patients entering trials and to ensure that a safe dose and delivery protocol, etc, are determined by running them. While it is very disappointing that two CLL patients died from TLS during the ABT-199 trials, the company has acted with appropriate caution despite the likely financial impact. Hopefully the company will be able to successful complete the approval process for ABT-199 as planned and benefit the company shareholders while providing those of us needing treatment with a hopefully better and safer alternative to currently available options.

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
2 Replies
jangreen profile image
jangreen

Hi I was in a trial. I felt I was given as much information as possible and was please with the care and treatment I received. It will not be untill years to come whether its been effective or not. Its always the risk you take.

Oleboyredw-uk profile image
Oleboyredw-uk

Having a large percentage of a company income from one source is a bad place to be for them. I''ve seen the effect on share price of a company where 60% of their income came from purchases by three big companies. Two of those stopped or nearly stopped purchases for a quarter. Big impact on bttom line ad 30% off share price not good.

The message for us... The companies need to research AND deliver new drugs it be healthy themselves. Let's all hope they stay healthy. :-)

Rob

Not what you're looking for?

You may also like...

ABT-199 Trial experience in Australia

Following are my notes on the presentation by Andrew Roberts, to the Australian Leukaemia...

Have Johnson & Johnson and AstraZeneca done one better than AbbVie, purchasing 55 percent of Acerta Pharma for acalabrutinib (ACP-196)?

"Earlier this year, AbbVie won an intense bidding war for Pharmacyclics, paying $21 billion for...

Clinical Trials studying COVID-19 vaccines in CLL: Some have begun/ others are coming!

Clinical Trials studying COVID-19 vaccines in CLL: In response to all those who have reached out to...

Scoring System for the Risk of Heart Problems in CLL Patients Treated with Ibrutinib: An Italian Model

An Italian scoring system worked better than 2 other risk models for predicting which patients with...

Reflections from Cardiff, news of CLL research and the changing trials landscape

Hi everyone After reflecting on yesterday's Cardiff CLLSA patient meeting and...